UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 62

Sortiert nach

Complete response in the axilla and the non-triple negative subtype are favourable prognostic factors for survival outcomes in inflammatory breast cancer

Breast (Edinburgh), 2023-06, Vol.69, p.481-490

2023

Link zum Volltext

Verfügbarkeit prüfen

Cannabinoids and Hormone Receptor-Positive Breast Cancer Treatment

Cancers, 2020-02, Vol.12 (3), p.525

2020

Link zum Volltext

Verfügbarkeit prüfen

Factors associated with a high level of unmet needs and their prevalence in the breast cancer survivors 1–5 years after post local treatment and (neo)adjuvant chemotherapy during the COVID-19: A cross-sectional study

Frontiers in psychology, 2022-10, Vol.13, p.969918-969918

2022

Link zum Volltext

Verfügbarkeit prüfen

Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer

Cancers, 2022-03, Vol.14 (7), p.1598

2022

Link zum Volltext

Verfügbarkeit prüfen

Symptoms of Anxiety and Depression Among Slovenian Breast Cancer Survivors Post-Treatment During the COVID-19 Pandemic: A Cross-Sectional Study

Zdravstveno varstvo, 2024-03, Vol.63 (1), p.55-62

2024

Link zum Volltext

Verfügbarkeit prüfen

Effect of combining CBD with standard breast cancer therapeutics

Advances in cancer biology - metastasis, 2022-07, Vol.4, p.100038, Article 100038

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of selective cyclin-dependent kinases 4/6 inhibitors in hormone-receptor-positive, HER2-negative advanced breast cancer – results from a real-world setting

Cancer treatment and research communications, 2020, Vol.25, p.100201-100201, Article 100201

2020

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of Treatment in Slovene Follicular Lymphoma Patients

Clinical lymphoma, myeloma and leukemia, 2015-10, Vol.15 (10), p.586-591

2015

Link zum Volltext

Verfügbarkeit prüfen

Recommendations for diagnosis and treatment of patients with breast cancer (part 2)

Onkologija, 2019-12, Vol.23 (2)

2019

Link zum Volltext

Verfügbarkeit prüfen

Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population

Breast cancer research and treatment, 2021-10, Vol.189 (3), p.689-699

2021

Link zum Volltext

Verfügbarkeit prüfen

Axillary ultrasound for predicting response to neoadjuvant treatment in breast cancer patients—a single institution experience

World journal of surgical oncology, 2023-09, Vol.21 (1), p.1-292, Article 292

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract P3-05-11: Cannabidiol increases potency of tamoxifen in inhibiting breast cancer cell viability

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P3-P3-05-11

2020

Link zum Volltext

Verfügbarkeit prüfen

Triple negative breast cancer - prognostic factors and survival

Radiology and oncology, 2011-03, Vol.45 (1), p.46-52

2011

Link zum Volltext

Verfügbarkeit prüfen

The association between baseline patient characteristics and alpelisib-induced hyperglycaemia in patients with HR+, HER2-, PIK3CA-mutated metastatic breast cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e13059-e13059

2023

Link zum Volltext

Verfügbarkeit prüfen

Report on isoelectric focusing trial of erythropoietin profiling in two cancer patients during chemotherapy and darbepoetin treatment

Acta chimica Slovenica, 2011-03, Vol.58 (1), p.139-143

2011

Link zum Volltext

Verfügbarkeit prüfen

Advancing HER2-low breast cancer management: enhancing diagnosis and treatment strategies

Radiology and oncology, 2024-06, Vol.58 (2), p.258-267

2024

Link zum Volltext

Verfügbarkeit prüfen

Early cardiotoxicity after adjuvant concomitant treatment with radiotherapy and trastuzumab in patients with breast cancer

Radiology and oncology, 2018-06, Vol.52 (2), p.204-212

2018

Link zum Volltext

Verfügbarkeit prüfen

Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial

Radiology and oncology, 2022-05, Vol.56 (2), p.238-247

2022

Link zum Volltext

Verfügbarkeit prüfen

Concurrent treatment with tamoxifen and CYP2D6 inibitors: clinical significance of drug interactions

Zdravniški vestnik (Ljubljana, Slovenia : 1992), 2012-08, Vol.81 (7-8)

2012

Link zum Volltext

Verfügbarkeit prüfen

Slabost in bruhanje pri bolnikih na sistemskem zdravljenju raka

Onkologija, 2009-06, Vol.13 (1), p.51-53

Simona Borštnar

2009

Link zum Volltext

Verfügbarkeit prüfen

The role of the urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in breast cancer

Zdravniški vestnik (Ljubljana, Slovenia : 1992), 2011-05, Vol.80 (5)

2011

Link zum Volltext

Verfügbarkeit prüfen

Prognostic value of systemic inflammatory response in early-stage triple-negative breast cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e14562-e14562

2023

Link zum Volltext

Verfügbarkeit prüfen

Mesto bisfosfonatov pri zdravljenju bolnikov z rakom

Onkologija, 2008-12, Vol.12 (2), p.108-113

Simona Borštnar

2008

Link zum Volltext

Verfügbarkeit prüfen

PD-L1 immune cell expression levels and clinical outcomes in advanced triple-negative breast cancer treated with atezolizumab

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e13066-e13066

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 62

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(59)
Mit Volltextzugriff
(60)

Publikationsform

Artikel
(62)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(26)
Life Sciences & Biomedicine
(25)
Oncology
(21)
Breast Cancer
(20)
Humans
(14)
Female
(13)
Breast Neoplasms - Drug Therapy
(7)
Erbb-2 Protein
(7)
Patients
(7)
Adult
(6)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(6)
Chemotherapy
(6)
Endocrine Therapy
(6)
Cancer
(5)
Disease-Free Survival
(5)
Male
(5)
Prognosis
(5)
Treatment Outcome
(5)
Aged
(4)
Biological And Medical Sciences
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Complete response in the axilla and the non-triple negative subtype are favourable prognostic factors for survival outcomes in inflammatory breast cancer

Cannabinoids and Hormone Receptor-Positive Breast Cancer Treatment

Factors associated with a high level of unmet needs and their prevalence in the breast cancer survivors 1–5 years after post local treatment and (neo)adjuvant chemotherapy during the COVID-19: A cross-sectional study

Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer

Symptoms of Anxiety and Depression Among Slovenian Breast Cancer Survivors Post-Treatment During the COVID-19 Pandemic: A Cross-Sectional Study

Effect of combining CBD with standard breast cancer therapeutics

Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial

Efficacy and safety of selective cyclin-dependent kinases 4/6 inhibitors in hormone-receptor-positive, HER2-negative advanced breast cancer – results from a real-world setting

Outcomes of Treatment in Slovene Follicular Lymphoma Patients

Recommendations for diagnosis and treatment of patients with breast cancer (part 2)

Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population

Axillary ultrasound for predicting response to neoadjuvant treatment in breast cancer patients—a single institution experience

Abstract P3-05-11: Cannabidiol increases potency of tamoxifen in inhibiting breast cancer cell viability

Triple negative breast cancer - prognostic factors and survival

The association between baseline patient characteristics and alpelisib-induced hyperglycaemia in patients with HR+, HER2-, PIK3CA-mutated metastatic breast cancer

Report on isoelectric focusing trial of erythropoietin profiling in two cancer patients during chemotherapy and darbepoetin treatment

Advancing HER2-low breast cancer management: enhancing diagnosis and treatment strategies

Early cardiotoxicity after adjuvant concomitant treatment with radiotherapy and trastuzumab in patients with breast cancer

Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial

Concurrent treatment with tamoxifen and CYP2D6 inibitors: clinical significance of drug interactions

Slabost in bruhanje pri bolnikih na sistemskem zdravljenju raka

The role of the urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in breast cancer

Prognostic value of systemic inflammatory response in early-stage triple-negative breast cancer

Mesto bisfosfonatov pri zdravljenju bolnikov z rakom

PD-L1 immune cell expression levels and clinical outcomes in advanced triple-negative breast cancer treated with atezolizumab

Suchergebnisse filtern